These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 6185342)

  • 41. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture.
    Bonadonna G
    Cancer Res; 1982 Nov; 42(11):4309-20. PubMed ID: 6181867
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy.
    Brusamolino E; Orlandi E; Morra E; Castelli G; Pagnucco G; Livraghi A; Astori C; Santagostino A; Lazzarino M; Bernasconi C
    Ann Oncol; 1994; 5 Suppl 2():53-7. PubMed ID: 7515648
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
    Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
    Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results.
    Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D
    J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855
    [No Abstract]   [Full Text] [Related]  

  • 45. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
    Andrieu JM; Colonna P
    J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
    [No Abstract]   [Full Text] [Related]  

  • 46. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy.
    Santoro A; Bonadonna G; Valagussa P; Zucali R; Viviani S; Villani F; Pagnoni AM; Bonfante V; Musumeci R; Crippa F
    J Clin Oncol; 1987 Jan; 5(1):27-37. PubMed ID: 2433409
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine and vinblastine (ABDV).
    Case DC; Young CW; Lee BJ
    Cancer; 1977 Apr; 39(4):1382-6. PubMed ID: 66972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
    J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical investigations of children with Hodgkin's disease at Stanford University Medical Center. A preliminary overview using low-dose irradiation and alternating ABVD/MOPP chemotherapy.
    Donaldson SS; Link MP; McDougall IR; Parker BR; Shochat SJ
    Cancer Treat Res; 1989; 41():307-15. PubMed ID: 2484294
    [No Abstract]   [Full Text] [Related]  

  • 50. MOPP versus ABVD and low-dose versus high-dose irradiation in Hodgkin's disease at intermediate and advanced stages: analysis of a meta-analysis by clinicians.
    Andrieu JM; Yilmaz U; Colonna P
    J Clin Oncol; 1999 Feb; 17(2):730-4. PubMed ID: 10080622
    [No Abstract]   [Full Text] [Related]  

  • 51. Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).
    Straus DJ; Myers J; Koziner B; Lee BJ; Clarkson BD
    Cancer Chemother Pharmacol; 1983; 11(2):80-5. PubMed ID: 6194913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
    Takenaka T; Mikuni C; Miura A; Sasaki T; Suzuki H; Hotta T; Hirano M; Fukuhara S; Sugiyama H; Nasu K; Dohi H; Kozuru M; Tomonaga M; Tajima K; Niimi M; Fukuda H; Mukai K; Shimoyama M
    Jpn J Clin Oncol; 2000 Mar; 30(3):146-52. PubMed ID: 10798542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
    Carella AM; Congiu AM; Gaozza E; Mazza P; Ricci P; Visani G; Meloni G; Cimino G; Mangoni L; Coser P
    J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
    Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Third-line salvage chemotherapy in Hodgkin's disease.
    Bonadonna G; Viviani S; Valagussa P; Bonfante V; Santoro A
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):23-5. PubMed ID: 2579440
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ABVD versus MOPP: which is better?
    Rosenberg SA
    J Clin Oncol; 1987 Jan; 5(1):7. PubMed ID: 2433410
    [No Abstract]   [Full Text] [Related]  

  • 57. [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV].
    Lopez M
    Clin Ter; 2001; 152(3):203-6. PubMed ID: 11692542
    [No Abstract]   [Full Text] [Related]  

  • 58. Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience.
    Bonadonna G; Santoro A; Gianni AM; Viviani S; Siena S; Bregni M; Zucali R; Lombardi F; Bonfante V; Gianni L
    Ann Oncol; 1991 Jan; 2 Suppl 1():9-16. PubMed ID: 1710489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Improved survival rates in Hodgkin's disease].
    Hayabuchi N; Jingu K; Miyoshi M; Hirata H; Masuda K; Shibuya T; Nishimura J; Komiyama S; Ishii E; Kikuchi M
    Gan No Rinsho; 1988 Apr; 34(5):698-704. PubMed ID: 2455073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.